Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03431285|
Recruitment Status : Unknown
Verified February 2018 by Mohammed Saeed Saad Alshahrani, Dammam University.
Recruitment status was: Recruiting
First Posted : February 13, 2018
Last Update Posted : February 20, 2018
Information provided by (Responsible Party):
Mohammed Saeed Saad Alshahrani, Dammam University
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||January 1, 2019|
|Estimated Study Completion Date :||February 27, 2019|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Alshahrani MS, Asonto LP, El Tahan MM, Al Sulaibikh AH, Al Faraj SZ, Al Mulhim AA, Al Abbad MF, Al Nahhash SA, Aldarweesh MN, Mahmoud AM, Almaghraby N, Al Jumaan MA, Al Junaid TO, Al Hawaj FM, AlKenany S, ElSayed OF, Abdelwahab HM, Moussa MM, Alossaimi BK, Alotaibi SK, AlMutairi TM, AlSulaiman DA, Al Shahrani SD, Alfaraj D, Alhazzani W. Study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease. Trials. 2019 May 27;20(1):286. doi: 10.1186/s13063-019-3394-4.